日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quantitative MYD88L265P and CXCR4S338X analysis to assess clinical trial performance in Waldenstrom macroglobulinemia

定量 MYD88L265P 和 CXCR4S338X 分析用于评估华氏巨球蛋白血症临床试验的性能

Tsakmaklis, Nickolas; Hunter, Zachary R; Liu, Xia; Kofides, Amanda; Liu, Shirong; Guerrera, Maria Luisa; Guijosa, Alberto; Sun, Hao; Hatcher, John M; Peachey, Abigail; Patterson, Christopher J; Meid, Kirsten; Gustine, Joshua; Branagan, Andrew R; Sarosiek, Shayna R; Castillo, Jorge J; Treon, Steven P

Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain

利用与假激酶结构域结合的赖氨酸反应性化合物对JAK2进行变构抑制

Primi, Marina C; Tavares, Maurício T; Hatcher, John M; Kang, Hyelim; Kresina, Tomás A C; Chakraborty, Sayan; Leroy, Emilie; Schmoker, Anna M; Jeon, Hyesung; Weisberg, Ellen L; Akatsu, Taisei; Griffin, James D; Scott, David A; Eck, Michael J

Repurposing pacritinib to target MYD88-mutated Waldenström macroglobulinaemia

将帕克替尼用于治疗MYD88突变型华氏巨球蛋白血症

Liu, Shirong; Kofides, Amanda; Liu, Xia; Hatcher, John M; Sun, Hao; Tsakmaklis, Nicholas; Guijosa, Alberto; Guerrera, Maria L; Pizzarella, Dominic; Peachey, Abigail L; Patterson, Christopher J; Hunter, Zachary R; Meid, Kirsten; Castillo, Jorge J; Sarosiek, Shayna R; Treon, Steven P

Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α

基于结构的截短型异二价化学探针IRE1α降解剂的设计

Zerfas, Breanna L; Liu, Yingpeng; Che, Jianwei; Donovan, Katherine A; Hatcher, John M; Huerta, Fidel; Metivier, Rebecca J; Nowak, Radosław P; Ragosta, Leah; Tsang, Tiffany; Fischer, Eric S; Jones, Lyn H

Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions

催化降解剂可有效解决EML4-ALK致癌融合蛋白中的激酶位点突变

Gao, Yang; Jiang, Baishan; Kim, Hellen; Berberich, Matthew J; Che, Jianwei; Donovan, Katherine A; Hatcher, John M; Huerta, Fidel; Kwiatkowski, Nicholas P; Liu, Yingpeng; Liuni, Peter P; Metivier, Rebecca J; Murali, Vineeth K; Nowak, Radosław P; Zhang, Tinghu; Fischer, Eric S; Gray, Nathanael S; Jones, Lyn H

Development of a highly potent and selective degrader of LRRK2

开发一种高效且选择性强的LRRK2降解剂

Hatcher, John M; Zwirek, Monika; Sarhan, Adil R; Vatsan, Prasanna S; Tonelli, Francesca; Alessi, Dario R; Davies, Paul; Gray, Nathanael S

Selective Macrocyclic Inhibitors of DYRK1A/B

DYRK1A/B 的选择性大环抑制剂

Powell, Chelsea E; Hatcher, John M; Jiang, Jie; Vatsan, Prasanna S; Che, Jianwei; Gray, Nathanael S

Development of Highly Potent and Selective Pyrazolopyridine Inhibitor of CDK8/19

高效选择性吡唑并吡啶类CDK8/19抑制剂的开发

Hatcher, John M; Vatsan, Prasanna S; Wang, Eric; Jiang, Jie; Gray, Nathanael S

Development of CDK2 and CDK5 Dual Degrader TMX-2172

CDK2 和 CDK5 双重降解剂 TMX-2172 的开发

Teng, Mingxing; Jiang, Jie; He, Zhixiang; Kwiatkowski, Nicholas P; Donovan, Katherine A; Mills, Caitlin E; Victor, Chiara; Hatcher, John M; Fischer, Eric S; Sorger, Peter K; Zhang, Tinghu; Gray, Nathanael S

Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation

选择性和不可逆共价配体开发与验证的最新进展

Zhang, Tinghu; Hatcher, John M; Teng, Mingxing; Gray, Nathanael S; Kostic, Milka